Literature DB >> 21672529

Mutated C-terminal fragments of Clostridium perfringens enterotoxin have increased affinity to claudin-4 and reversibly modulate tight junctions in vitro.

Azusa Takahashi1, Masuo Kondoh, Hiroshi Uchida, Yohei Kakamu, Takao Hamakubo, Kiyohito Yagi.   

Abstract

Passage across epithelial cell sheets is the first step in drug absorption. Tight junctions (TJs) are located between adjacent epithelial cells and seal the intercellular space preventing leakage of solutes. Claudin, a tetra-transmembrane protein family, is a pivotal functional and structural component of the TJ barrier. Modulation of the claudin-based TJ seal is a strategy for mucosal drug absorption. We previously found that a claudin-4 binder, a C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE194), was a modulator of the TJ seal and a potent mucosal absorption enhancer. In the present study, we attempted to improve claudin-4 binders by modification of C-CPE194. Substitution of Asn at position 309 and Ser at position 313 with Ala increased the affinity to claudin-4 by 9.9-fold as compared to C-CPE194. Deletion of 10 amino acids in the N-terminal domain of the double-alanine-substituted mutant increased affinity to claudin-4 by 23.9-fold as compared to C-CPE194. These C-CPE194 mutants reversibly modulated the TJ seal in human intestinal epithelial cell sheets. The N-terminal-truncated mutant was the most potent modulator of the TJ seal. These findings indicate that the C-CPE mutant may be a promising lead for the development of a clinical TJ modulator.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672529     DOI: 10.1016/j.bbrc.2011.05.161

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

2.  In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin.

Authors:  Sina Arabshahi; Abdollah Derakhshandeh; Bahar Nayeri Fasaei; Aytak Novinrooz
Journal:  Mol Biol Rep       Date:  2019-08-31       Impact factor: 2.316

3.  Structural basis for disruption of claudin assembly in tight junctions by an enterotoxin.

Authors:  Takehiro Shinoda; Naoko Shinya; Kaori Ito; Noboru Ohsawa; Takaho Terada; Kunio Hirata; Yoshiaki Kawano; Masaki Yamamoto; Tomomi Kimura-Someya; Shigeyuki Yokoyama; Mikako Shirouzu
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

4.  In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate.

Authors:  Sina Arabshahi; Bahar Nayeri Fasaei; Abdollah Derakhshandeh; Aytak Novinrooz
Journal:  Bioengineered       Date:  2017-11-30       Impact factor: 3.269

Review 5.  Claudins in intestines: Distribution and functional significance in health and diseases.

Authors:  Zhe Lu; Lei Ding; Qun Lu; Yan-Hua Chen
Journal:  Tissue Barriers       Date:  2013-05-30

6.  Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway.

Authors:  Tsuyoshi Kono; Masuo Kondoh; Daisuke Kyuno; Tatsuya Ito; Yasutoshi Kimura; Masafumi Imamura; Takayuki Kohno; Takumi Konno; Tomohisa Furuhata; Norimasa Sawada; Koichi Hirata; Takashi Kojima
Journal:  Pharmacol Res Perspect       Date:  2015-12-20

7.  Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay.

Authors:  Akihiro Watari; Miki Kodaka; Koji Matsuhisa; Yuta Sakamoto; Kota Hisaie; Norihito Kawashita; Tatsuya Takagi; Yoshiaki Yamagishi; Hidehiko Suzuki; Hirofumi Tsujino; Kiyohito Yagi; Masuo Kondoh
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.